anti α sma  (Bioss)

Journal: Biochemistry and Biophysics Reports

Article Title: LncRNA RMST knockout inhibits fibrosis by down-regulating Smad3 during mouse skin wound healing

doi: 10.1016/j.bbrep.2025.102386

Figure Lengend Snippet: RMST-KO reduces fibrosis in mouse skin wound healing. (A) Differences of RMST expression between unwounded skin and the 21 dps group. (B) Agarose gel electrophoresis confirmed the successful knockout of RMST. (C) QPCR assay showing the expression of RMST 21 dps. (D) H&E and Masson staining of the wounds 21 dps as indicated. (E–F) RMST-KO reduced the (E) thickness and (F) area of neogenic fibrous tissue at 21 dps. (G–H) QPCR showing the COL1A1 and α-SMA levels were significantly decreased in the RMST-KO group compared to the WT group 21 dps. (I) Representative blot of COL1A1 and α-SMA 21 dps. (J–K) Statistical analysis of the immunoblot bands indicated that RMST-KO significantly suppressed the expression of COL1A1 and α-SMA 21 dps. Data were shown as mean ± SD, n = 6, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: α-SMA (67735-1-Ig) , 1:50000 , Proteintech.

Techniques: Expressing, Agarose Gel Electrophoresis, Knock-Out, Staining, Western Blot

Journal: Biochemistry and Biophysics Reports

Article Title: LncRNA RMST knockout inhibits fibrosis by down-regulating Smad3 during mouse skin wound healing

doi: 10.1016/j.bbrep.2025.102386

Figure Lengend Snippet: Smad3-OE reversed the fibrosis suppression resulting from RMST-KO. (A) QPCR confirmed the upregulating effect of Smad3-OE lentivirus. (B) Representative blot of Smad3 under the effect of Smad3-OE and/or RMST-KO. (C) Statistical analysis of the immunoblot bands. (D) H&E and Masson staining of the wounds as indicated. (E–F) Statistical analysis of the (E) thickness and (F) area of neogenic fibrous tissue 21 dps. (G–I) qPCR detection of fibrosis markers and proteins in classical fibrosis pathways, including COL1, α-SMA, and TGF-β1. (J–M). Representative blot of COL1, α-SMA, and TGF-β1. (N–O) qPCR detection of inflammatory cytokines TNF-α and IL-1β. (P–R) Representative blot of TNF-α and IL-1β. Data were shown as mean ± SD, n = 6, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: α-SMA (67735-1-Ig) , 1:50000 , Proteintech.

Techniques: Western Blot, Staining

Journal: Neural Regeneration Research

Article Title: Pathological axonal enlargement in connection with amyloidosis, lysosome destabilization, and bleeding is a major defect in Alzheimer’s disease

doi: 10.4103/NRR.NRR-D-24-01440

Figure Lengend Snippet: Blood and vascular proteins co-exist with intracellular Aβ in neural cells in AD frontal lobe tissues and may also be related to lysosome instability. (A) Representative images showing the co-expression of blood-related markers HBA (green, Alexa Fluor 488) and Aβ (red, Alexa Fluor 594). (B) Representative images showing the co-expression of vascular markers ACTA2 (green, Alexa Fluor 488) and Aβ (red, Alexa Fluor 594). (C) Representative images showing the co-expression of vascular markers ColIV (red, Alexa Fluor 594) and Aβ (green, Alexa Fluor 488). The colocalization of markers is indicated by yellow arrows. Two small blood vessels are indicated by asterisks in the ColIV staining panel. (D) Intracellular HBA (green, Alexa Fluor 488) expression domains overlapped with the region of lysosomal destabilization, which is indicated by enlarged and clustered lysosomal compartments and diffuse Cathepsin D staining (red, Alexa Fluor 594, marked with yellow dashed circles). Control HBA-unaffected lysosomes are indicated by white arrows. Scale bars: 25 μm. ACTA2: Smooth muscle actin alpha 2; AD: Alzheimer’s disease; Aβ: amyloid-β; ColIV: collagen type IV; HBA: hemoglobin.

Article Snippet: The following primary antibodies and dilutions were used: Aβ (1:200, Abcam, Cambridge, UK, Cat# ab201061, RRID: AB_2722492), Aβ/AβPP (1:200, CST, Danvers, MA, USA, Cat# 2450, RRID: AB_490857), phos-tau (1:200, Abcam, Cat# ab151559, RRID: AB_2893278), microtubule associated protein 2 (MAP2; 1:200, Proteintech, Rosemont, IL, USA, Cat# 17490-1-AP, RRID: AB_2137880), apolipoprotein E (ApoE; 1:200, Abcam, Cat# ab183597, RRID: AB_3331650), Sortilin1 (1:200, Abcam, Cat# ab263864, RRID: AB_2884942), alpha-hemoglobin (HBA; 1:200, Abcam, Cat# ab92492, RRID: AB_10561594), Cathepsin D (1:200, Abcam, Cat# ab75852, RRID: AB_1523267), lysosome-associated membrane protein 2 (Lamp2; 1:100, Proteintech, Cat# 66301-1-Ig, RRID: AB_2881684), Cathepsin D (1:100, Proteintech, Cat# 66534-1-Ig, RRID: AB_2881897), glycosylated hemoglobin type A1C (HbA1c; 1:100, OkayBio, Nanjing, Jiangsu, China, Cat# K5a2), hemin (1:100, Absolute Antibody, Redcar, UK, Cat# 1D3), advanced glycation end products (AGE; 1:200, Abcam, Cat# ab23722, RRID: AB_447638), collagen type IV (ColIV; 1:200, Abcam, Cat# ab236640), and smooth muscle actin alpha 2 (ACTA2; 1:400, Proteintech, Cat# 23081-1-AP, RRID: AB_2815024).

Techniques: Expressing, Staining, Control